Children's Oncology Group's 2013 blueprint for research

Soft tissue sarcomas

Douglas S. Hawkins, Sheri L. Spunt, Stephen X. Skapek

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.

Original languageEnglish (US)
Pages (from-to)1001-1008
Number of pages8
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Sarcoma
Rhabdomyosarcoma
Vascular Endothelial Growth Factor A
Research
Aggressive Fibromatosis
Clinical Trials
Pediatrics
Drug Therapy
Therapeutics
Neoplasms

Keywords

  • Children
  • Malignancies
  • Non-rhabdomyosarcoma soft tissue sarcoma
  • Rhabdomyosarcoma
  • Sarcoma

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Children's Oncology Group's 2013 blueprint for research : Soft tissue sarcomas. / Hawkins, Douglas S.; Spunt, Sheri L.; Skapek, Stephen X.

In: Pediatric Blood and Cancer, Vol. 60, No. 6, 06.2013, p. 1001-1008.

Research output: Contribution to journalArticle

Hawkins, Douglas S. ; Spunt, Sheri L. ; Skapek, Stephen X. / Children's Oncology Group's 2013 blueprint for research : Soft tissue sarcomas. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 6. pp. 1001-1008.
@article{2ba359ee6b464b2aa96e65374bfa586e,
title = "Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas",
abstract = "In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.",
keywords = "Children, Malignancies, Non-rhabdomyosarcoma soft tissue sarcoma, Rhabdomyosarcoma, Sarcoma",
author = "Hawkins, {Douglas S.} and Spunt, {Sheri L.} and Skapek, {Stephen X.}",
year = "2013",
month = "6",
doi = "10.1002/pbc.24435",
language = "English (US)",
volume = "60",
pages = "1001--1008",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Children's Oncology Group's 2013 blueprint for research

T2 - Soft tissue sarcomas

AU - Hawkins, Douglas S.

AU - Spunt, Sheri L.

AU - Skapek, Stephen X.

PY - 2013/6

Y1 - 2013/6

N2 - In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.

AB - In the US, approximately 850-900 children are diagnosed each year with soft tissue sarcomas (STS). Key findings from recent Children's Oncology Group (COG) clinical trials include safe reduction in therapy for low risk rhabdomyosarcoma (RMS), validation of FOXO1 fusion as a prognostic factor, a modest improvement in outcome for high-risk RMS, and a biologically designed non-cytotoxic therapy for pediatric desmoid tumor. Planned Phase 2 trials include targeted agents for VEGF/PDGF, mTOR, and IGF-1R for children with RMS and VEGF for children with non-RMS STS (NRSTS). For RMS, COG Phase 3 trials potentially will explore VEGF/mTOR inhibition or chemotherapy interval compression. For NRSTS, a COG Phase 3 trial will explore VEGF inhibition.

KW - Children

KW - Malignancies

KW - Non-rhabdomyosarcoma soft tissue sarcoma

KW - Rhabdomyosarcoma

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84876442851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876442851&partnerID=8YFLogxK

U2 - 10.1002/pbc.24435

DO - 10.1002/pbc.24435

M3 - Article

VL - 60

SP - 1001

EP - 1008

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -